NPPB and lymphoproliferative syndrome: In the context of CVDs in patients with lymphoproliferative disorders, several serum biomarkers have been suggested for risk stratification, including pro-B-type natriuretic peptide (proBNP), high-sensitivity C-reactive protein (hs-CRP), troponins, and brain natriuretic peptide (BNP).